Denali Therapeutics Inc.
DNLI
$15.49
$0.261.71%
NASDAQ
| 06/30/2025 | 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | |
|---|---|---|---|---|---|
| Net Income | -14.15% | -230.75% | -191.12% | -243.56% | -226.90% |
| Total Depreciation and Amortization | -51.09% | -75.77% | -93.47% | -54.13% | -54.22% |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | 93.82% | 75.82% | -5.60% | -36.04% | -44.96% |
| Change in Net Operating Assets | 287.60% | 103.30% | 105.84% | 104.14% | 91.65% |
| Cash from Operations | 10.55% | 11.45% | 2.88% | -9.23% | -29.56% |
| Capital Expenditure | -63.11% | -53.13% | -22.98% | 16.06% | 42.47% |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | 372.03% | 506.65% | -127.78% | -372.14% | -881.99% |
| Cash from Investing | 344.96% | 444.70% | -135.60% | -485.85% | -391.09% |
| Total Debt Issued | -- | -- | -- | -- | -- |
| Total Debt Repaid | -- | -- | -- | -- | -- |
| Issuance of Common Stock | -97.14% | -96.63% | 2,804.61% | 65.67% | 63.18% |
| Repurchase of Common Stock | -- | -- | -- | -- | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | 0.00% | 0.00% | -- | -- | -- |
| Cash from Financing | -104.84% | -103.82% | 2,617.76% | 57.68% | 63.03% |
| Foreign Exchange rate Adjustments | -- | -- | -- | -- | -- |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | 218.79% | 71.99% | 152.67% | -294.68% | -148.67% |